 |
| (Click to Enlarge) |
3D System Corp. (NYSE: DDD) is a provider for 3D content-to-print technology. The stock jumped almost 10%, made a new 52w high and closed very close to the high with a great volume on Friday. 50-Day MA has been a very good track of the stock prices since the bullish MA crossover in late Feb with very little breakout of the MA trendline. With the MACD just crossed to +ve area and Slow STO making higher highs and higher lows. I think DDD is a very hot stock to put on your radar. I think the long term trend is still intact and does not seem to reverse any time soon.
 |
| (Click to Enlarge) |
J.P. Morgan Chase & Co. (NYSE: JPM)
The technicals for JPM can be bullish and bearish depends on how you are looking at it. Slow STO and MACD crossover shows bullish signs. The stock has gained in 5 trading days straight with decent volume. However, 50-day crossing 200-day MA from above is golden bearish and sell signal to many professional technicians. But the bright side is 50-day MA starts trending upwards, showing a round bottoming. Definitely put JPM on your radar next week. If the stock break through $37 (a round number resistance) with good volume, I would definitely add JPM in my portfolio with using % stop.
 |
| (Click to Enlarge) |
Stratasys, Inc. (NASDAQ: SSYS) is a company doing similar 3D printing business as NYSE:DDD I mentioned above. MACD in positive level with bullish STO divergence. Similar to DDD, 50-day MA seems to show the price trend nicely and signal oversold area for SSYS. Both 50 and 200-day MA is trending upwards and although the stock has gained almost 9% on Friday, it still has a little bit trip to go until it reaches the upper band of the channel I have drawn. For comparison, SSYS has higher possible return for medium-to-short term trades (below 2-3 months holding). But DDD seems to be less volatile and suitable for longer term investment
 |
| (Click to Enlarge) |
Arena Pharmaceuticals (NASDAQ: ARNA) has got the first anti-obesity drug approved by the FDA in the U.S. in late June. The stock has been very popular for speculative purpose before the approval. It keeps getting twitted and reported on WSJ. However, after the approval, the stocks has been going red. Although slow STO shows oversold signal and RSI might seem okay for a stock running up for so long, and $9.42 seems reasonable for a pullback, I think it is not suitable to add ARNA into your portfolio unless you have high risk tolerance. Recently, a anti-obesity drug offered by Cali-based Vivus has been approved by FDA. And based on several news reports I have read, the Arena drug appears to need a lot of supplements in order to have successful results. The drug itself is approved but not the procedure, etc. Correct me if I am wrong. But with vivus as a rival and unknown results and popularity of such drug, a pharmaceutical company based just on some ideas and single drug product should be avoided, especially for ARNA which has been such speculative in price movement.
